Nurix Pharma - NRIX Quarterly EPS earnings growth

Corporate company logo of Nurix Therapeutics, Inc. (NRIX)

High barriers to entry in the protein degradation sector and strict regulatory oversight protect the assets of Nurix Therapeutics (NRIX). The quarterly EPS trend profile visualizes current financial trends, where the 558.30 indicator determines the metric's magnitude. Partnerships with pharma behemoths strengthen the market moat, while the implementation of unique PROTAC molecules will provide the company with pricing power upon the success of lymphoma therapies.

nurixtx.com (NRIX) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Nurix Therapeutics

- share price and consensus valuation forecast:
Fundamental company valuation:nurixtx.com - NRIX
Flagship merchandise of nurixtx.com

This indicator measures the quarterly rate of change in earnings per share, reflecting the efficiency of capital generation. Growth in this metric signals business scaling, while stagnation warns of the risk of overpaying for the asset. By analyzing the quarterly earnings per share trend, an investor assesses the company's fundamental stability. For Nurix Therapeutics (NRIX), this figure is volatile due to a dependence on partner payments. Irregular cash inflows during the development of oncology drugs make cash flows difficult to predict.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Tyra Biosciences Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (immuneering.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)